DAY THREE - Stream A: Cell Therapy & Regenerative Medicine

last modified: 22 May '12

Please enable javascript to see more information on speakers

9am

Chairman’s opening remarks

Prof. Chris Mason

Prof. Chris Mason MBBS, PhD, FSB, FRCSI, FRCS Stem Cell & Regenerative Medicine Bioprocessing Unit Advanced Centre for Biochemical Engineering University College London Mason is internationally recognized to be at the forefront of the emerging...

more..

› Prof. Chris Mason, Chair of Regenerative Medicine Bioprocessing, UCL

IMPLEMENTING STEM CELLS IN PIONEERING THERAPEUTIC APPLICATIONS

9.10am

The role of stem cell therapy in solid organ transplantation

Martin Birchall

Martin Birchall trained in medicine at Jesus College Cambridge and in ENT Surgery in London, Liverpool and Brisbane. He studied for a higher degree at the Royal Postgraduate Medical School and was the first surgeon to be awarded a Wellcome Trust...

more..

First synthetic organ transplant saves cancer patient
What were the challenges to building the trachea and correctly differentiating the stem cells?
What teachings can be taken forward to build more complex organs?
What does the future hold for using stem cells to engineer replacement parts?

› Martin Birchall, Professor of Laryngology, UCL

9.35am

Dynamics behind the Pervasis/Shire deal

Fred Chereau

Mr. Chereau assumed the role of President and Chief Operating Office at Pervasis Therapeutics in September 2008. Prior to Pervasis, Mr. Chereau was the Vice President and General Manager of Genzyme Cardiovascular, a business unit of Genzyme...

more..

Dean Tozer

Dean Tozer is Senior Vice President at Advanced BioHealing, Inc. (ABH). In this role he oversees marketing, corporate development, reimbursement, government affairs, product development, various regulatory functions and international...

more..

10am

Olfactory-derived neural progenitors; stable, versatile, adult, autologous cells for neurodegenerative diseases and disorders

Dr. Fred Roisen

Fred J. Roisen, Ph.D., founder and CSO of RhinoCyte™, Inc., is professor and chair of the Department of Anatomical Sciences and Neurobiology in the School of Medicine at the University of Louisville. He holds a B.S. in biochemistry from Northeastern ...

more..

Characterization, differentiation and stability
Platform development for spinal cord Injury, Parkinson’s disease, ALS & MS
Pathway and progress to the clinic

› Dr. Fred Roisen, Chief Scientific Officer, Rhinocyte

10.25am

Organ-specified cardiopoietic stem cell therapy and related technologies for regenerative cardiovascular medicine

Christian Homsy

Christian Homsy, Chief Executive Officer (CEO) of Cardio3 BioSciences and Member of the Board as Executive Director – Christian Homsy obtained his Medical Doctorate at the University of Louvain and holds an MBA from the IMD in Lausanne...

more..

· The Cardiopoiesis technology platform

· The C3BS-CQR-1 (C-Cure) multicenter randomized trial : cardiopoietic stem cell transplantation in heart failure

· From Phase II to Phase III

› Christian Homsy, CEO, Cardio3

10.40am

Morning refreshments

11.10am

Endometrial regenerative cells: specialized angiogenic MSC with broad clinical potential

Alan Lewis

Alan Lewis is currently an advisor to various Biopharma companies in the regenerative medicine space. He was recently CEO of Ambit Biosciences, the JDRF and Novocell( Viacyte). He also served as CEO of Signal Pharmaceuticals before it was acquired...

more..

ERC are specialized MSC derived from endometrium
Unique properties compared to other MSC sources: higher angiogenic growth factor production, higher proliferative rare, unique gene profile
Medistem is clinically pursing 60 patient cardiac trials (RECOVER-ERC), which DSMB approved continuation after one month safety review of first 5 patients treated and CLI trial in US

› Alan Lewis, Scientific Advisor, Medistem

11.35am

Invention process and new technology development for stem cell manufacturing

Jose Castillo

Degree in Chemical Engineering, ULB, Belgium PhD in Applied Sciences (organic chemistry), ULB, Belgium Best Business Plan Award, Solvay Business School, Belgium Jose is an inspired inventor with a broad R&D experience in university...

more..

· Commercial success linked to the ability to industrialize the manufacturing process

· Overcoming challenges in terms of consistency, reproducibility and safety with knock-on problems for QA and QC

· The innovation processes to design the future technological solutions and strategies for stem cell manufacturing

· How to translate stem cell biological and production requirements into innovative cell processing devices?

› Jose Castillo, Global Director Cell Culture Technologies, ATMI

CORD BLOOD BANKING

12pm

Public banking: collecting and storing umbilical cord blood stem cells

Guy Parkes

Guy Parkes is Head of Special Projects at Anthony Nolan having worked there since 1999. His primary responsibility is to lead the Charity’s Cord Blood Programme, which was established in 2008 to complement the adult stem cell donor Register that the ...

more..

The storage of umbilical cord blood stem cells through a public banking model
What is the societal view of the stem cell industry?

› Guy Parkes, Head of Special Products, Anthony Nolan Trust

12.25pm

Private banking: incorporating cord blood banking into your existing business model

Greg Bonfiglio

Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC – an investment and advisory firm focused solely on regenerative medicine. Proteus provides fund management, consulting, and investment banking services to the regenerative medicine...

more..

Where does private cord blood banking initiatives fit into the regenerative medicine market?
How might a public and private link in terms of cord blood banking drive the industry on?